ABBV Stock Analysis: Abbvie Inc
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients.
- Latest close
- $262.82
- 20-day change
- +1.00%
- Trend state
- LEAN BULL
- Classification
- Healthcare · Drug Manufacturers - General
Market context
Abbvie Inc moved +1.00% over the latest 20-session window. BullRecon currently classifies the broader setup as LEAN BULL.
Latest report
The latest cached company filing period (FY2025 · $61.2B revenue · $4.2B net income) is used alongside annual and quarterly history. Values remain tied to their reported period.
Six-dimension read
Quality is currently the strongest dimension at 5.8/6, while Value is the lowest at 3.3/6. Scores are comparative research signals, not forecasts.